TargaZyme, Inc. Receives Orphan Drug Designation To TZ101 For Use With Regulatory T Cells To Prevent & Reduce The Severity Of Graft Versus Host Disease In Patients Eligible For Hematologic Stem Cell Transplantation
SAN DIEGO, February 10, 2015: Orphan designation provides 7-year post approval marketing exclusivity, tax credits and elimination of FDA prescription drug user fees Targazyme Inc., a clinical-stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for stem cell transplantation, immunotherapy, gene therapy and regenerative medicine, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TZ101 to prevent and reduce the severity and incidence of graft vs. host disease (GVHD) in patients eligible for hematologic stem cell transplant. GVHD is a serious, life-threating complication of stem cell transplantation. Orphan drug status